Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Instil BioTIL -1.56%29 3-Year EPS without NRI Growth Rate is 39.00% as of Jun. 2026, which is 863% above its 10-year median of 4.05. GuruFocus rates TIL with a GF Score™ of 29/100. The stock has 3 warning signs investors should review. Among 1,160 Biotechnology companies, Instil Bio ranks better than 76.38% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 39.00% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 11.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 7 years, the highest 3-Year average EPS without NRI Growth Rate of Instil Bio was 39.00% per year. The lowest was -141.30% per year. And the median was 4.05% per year.
Instil Bio (NAS:TIL) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Instil Bio 3-Year EPS without NRI Growth Rate Related Terms
TIL vs ATYR, AURX, ELOX: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Instil Bio's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instil Bio 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Instil Bio's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Instil Bio's 3-Year EPS without NRI Growth Rate falls into.
Instil Bio 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 39.00% mean?
Instil Bio (TIL) has a 3-Year EPS without NRI Growth Rate of 39.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Instil Bio and its competitors. This is 863% above median its historical median of 4.05. According to the industry distribution chart, Instil Bio ranks #274 out of 1160 companies in the Biotechnology industry, placing it in the top 23.6%.
Is Instil Bio's 3-Year EPS without NRI Growth Rate too high?
Instil Bio's current 3-Year EPS without NRI Growth Rate of 39.00% is 863% above median its 10-year median of 4.05. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 15.95. Instil Bio's value of 39.00% is 144.5% above this industry median. Based on the distribution chart, Instil Bio ranks #274 out of 1160 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Instil Bio has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Instil Bio's 3-Year EPS without NRI Growth Rate compare to ATYR and AURX?
According to the Biotechnology industry distribution chart, Instil Bio ranks #274 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places Instil Bio in the top 24% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 15.95. Instil Bio's value of 39.00% is 144.5% above this benchmark. While the company's 10-year median is 4.05 vs. the industry median of 15.95, Instil Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 15.95, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Instil Bio's current 3-Year EPS without NRI Growth Rate of 39.00% is 144.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Instil Bio and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Instil Bio's current 3-Year EPS without NRI Growth Rate is 39.00%, which is 863% above median its own 10-year median of 4.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instil Bio stock overvalued right now?
Instil Bio (TIL) has a current 3-Year EPS without NRI Growth Rate of 39.00%. The current 3-Year EPS without NRI Growth Rate is 39.00%, which is 863% above median its 10-year median of 4.05 and 144.5% above the Biotechnology industry median of 15.95. Instil Bio's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Instil Bio (TIL), the current 3-Year EPS without NRI Growth Rate is 39.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
29GF Score
Get the complete analysis for TIL
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TIL has been successfully added to your 
